SCHEMBL13415674

SCHEMBL13415674

CCc1ccc(OF)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
CYP2C19 P33261 1/20 0.45
TP53 P04637 1/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
CYP2A6 P11509 2/20 0.41
LPL P06858 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
CYP1A2 P05177 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
RAB9A P51151 1/20 0.39
SOD1 P00441 1/20 0.39
CA2 P00918 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8925998 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TP53LMNAALDH1A1
SCHEMBL11725689 0.78 TAAR1 (0.52) SMN1; SMN2CYP2C19TP53LMNAALDH1A1
SCHEMBL475215 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TP53LMNAALDH1A1
SCHEMBL36295 0.76 TP53 (0.67) SMN1; SMN2TP53LMNAALDH1A1TAAR1
SCHEMBL30878 0.76 CA12 (0.61) SMN1; SMN2TP53LMNAALDH1A1MAPT
SCHEMBL155707 0.75 TSHR (0.58) TP53LMNAALDH1A1MAPTL3MBTL1
SCHEMBL765494 0.75 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TP53LMNAALDH1A1
SCHEMBL11504608 0.74 SMN1; SMN2 (0.50) SMN1; SMN2CYP2C19TP53LMNAALDH1A1
SCHEMBL5929490 0.74 MAPT (0.62) SMN1; SMN2LMNAALDH1A1MAPTHPGD
SCHEMBL22404037 0.74 SMN1; SMN2 (0.45) SMN1; SMN2CYP2C19TP53LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687155-B2 Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency CANON KABUSHIKI KAISHA (JP) 2010-03-30 US disclosed
US-20090184634-A1 LUMINESCENCE DEVICE AND DISPLAY APPARATUS CANON KABUSHIKI KAISHA (JP) 2009-07-23 US disclosed
US-20070212570-A1 Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency CANON KABUSHIKI KAISHA (JP) 2007-09-13 US disclosed
EP-1345943-B1 INHIBITORS OF PAPILLOMA VIRUS BOEHRINGER INGELHEIM CA LTD (CA) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090184634-A1 LUMINESCENCE DEVICE AND DISPLAY APPARATUS SOD1, NLRP1, LUC7L2 SMN1; SMN2 3616/4885CYP2C19 439/4885TP53 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.